QLT Inc. Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy

VANCOUVER, British Columbia, March 19, 2012 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced that its commercial product, Visudyne® (verteporfin for injection), was granted orphan drug designation for the potential treatment of chronic or recurrent central serous chorioretinopathy (CSC) from the U.S. Food and Drug Administration (FDA).

Back to news